Skip to main content
. 2023 May 17;129(2):249–265. doi: 10.1038/s41416-023-02282-2

Fig. 8. Schematic model of BRAFi and diclofenac effects on metabolic processes.

Fig. 8

Schematic representation of the possible molecular mechanism underlying the synergism between diclofenac and vemurafenib/dabrafenib (PLX4032 and DBR) in BRAF-mutated papillary and anaplastic thyroid carcinomas. Created with Biorender.com.